News
* ONCOQUEST SIGNS A DEFINITIVE AGREEMENT TO SELL DRUG PORTFOLIO TO DUAL INDUSTRIAL FOR U.S. $300 MILLION AND COMMITMENT TO FUND THE OREGOVOMAB PHASE 3 CLINICAL TRIAL IN FRONTLINE OVARIAN CANCER ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback